Standard BioTools (LAB) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precipio (PRPO) has outperformed Standard BioTools (LAB) over the past year, losing 29.2% versus a loss of 54.3%. Over five years, PRPO leads with a -54.6% price change compared with -86.5% for LAB. Standard BioTools is the larger company by market cap ($249.1 million vs $31.1 million), about 8.0 times the size, while Precipio is growing revenue faster (+29.8% vs -6.2%).
Precipio converts more of its revenue into profit, with a net margin of -1.5% versus -87.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LAB | PRPO |
|---|---|---|
| Share price | $0.631 | $17.35 |
| Market cap | $249.11M | $31.11M |
| 1-day change | +2.82% | -6.17% |
| YTD return | -50.70% | -24.50% |
| 1-year return | -54.28% | -29.18% |
| 5-year return | -86.55% | -54.58% |
| Forward P/E | — | 44.49 |
| EPS (TTM) | $-0.09 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.33M | $24.05M |
| Revenue growth (YoY) | -6.24% | +29.77% |
| Net income (latest FY) | $-74.90M | $-363.00K |
| Gross margin | 49.86% | 44.52% |
| Operating margin | -129.20% | -5.00% |
| Net margin | -87.77% | -1.51% |
| 52-week high | $1.72 | $33.63 |
| 52-week low | $0.39 | $17.30 |
| Distance from 52-week high | -63.31% | -48.41% |
| Analyst consensus | none | — |
| Avg. price target upside | +113.95% | — |
| Average volume | 1.16M | 79.50K |
| Shares outstanding | 394.79M | 1.79M |
| Employees | 385 | 61 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Standard BioTools is about 8.0 times larger than Precipio by market value ($249.11M vs $31.11M).
- PRPO has outperformed LAB by 25.1 percentage points over the past year.
- Precipio is more profitable, keeping -1.5 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.
- Precipio grew revenue faster in its latest fiscal year (+29.77% vs -6.24%).
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
LAB vs PRPO FAQ
Which is bigger, Standard BioTools or Precipio?
Standard BioTools (LAB) is larger, with a market capitalization of $249.11M compared with $31.11M for Precipio (PRPO).
Which stock has performed better over the past year, LAB or PRPO?
PRPO returned -29.18% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Standard BioTools and Precipio in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.